Aethlon Medical has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2024, primarily to include Part III information previously omitted. The amendment provides comprehensive details on director and executive compensation, corporate governance structures, and related party transactions.Key leadership changes include James B. Frakes serving as Interim CEO and CFO since November 2023, following the departure of former CEO Charles J. Fisher Jr. The company's board consists of five directors, with Edward G. Broenniman as Chairman. Executive compensation includes base salaries ranging from $390,000 to $500,000 for key officers, with additional equity-based incentives.The amendment also details the company's director compensation policy, which provides annual retainers and equity grants to non-employee directors. The filing includes updated information on beneficial ownership, with current directors and executive officers collectively holding approximately 1.0% of outstanding shares. The company maintains comprehensive indemnification agreements with its officers and directors.

Aethlon Medical has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2024, primarily to include Part III information previously omitted. The amendment provides comprehensive details on director and executive compensation, corporate governance structures, and related party transactions.Key leadership changes include James B. Frakes serving as Interim CEO and CFO since November 2023, following the departure of former CEO Charles J. Fisher Jr. The company's board consists of five directors, with Edward G. Broenniman as Chairman. Executive compensation includes base salaries ranging from $390,000 to $500,000 for key officers, with additional equity-based incentives.The amendment also details the company's director compensation policy, which provides annual retainers and equity grants to non-employee directors. The filing includes updated information on beneficial ownership, with current directors and executive officers collectively holding approximately 1.0% of outstanding shares. The company maintains comprehensive indemnification agreements with its officers and directors.